Greece: Greece introduces new pharmaceutical pricing provisions

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Greece: Greece introduces new pharmaceutical pricing provisions

The legal provisions regarding the pricing of pharmaceutical products have been amended several times during the last decade in an effort to address the issue of very high pharma expenditure and its impact on hospitals and the social security system and to create a stable and predictable reference pricing framework.

The last amendment in the legal provisions was introduced into the Greek legal system by a decision from the minister of health in May 2019.

According to the new provisions, the price of a reference medicinal product will be based on the average of the two lowest prices in the EU, amending the basis previously applicable, which was the three lowest prices in the EU. The price of generic products is 35% lower than that of reference products.

While the new system includes several provisions to ensure a control on the prices as well as to make sure that no product's price is increased more than 10% from its last price, the most important amendment from an IP perspective, is that the provisions existing in the former law, according to which the launch of a generic product in the Greek market would result in a 50% drop in the price of the reference product have been removed.

The launch of a generic product should therefore, contrary to what was applicable before May 2019, have no direct impact, from a statutory perspective, on the price of a reference product, which will be calculated on the basis of the mechanism provided in the new legal provisions.

kilimiris.jpg

Constantinos Kilimiris


Patrinos & Kilimiris7, Hatziyianni Mexi Str.GR-11528 AthensGreeceTel: +30210 7222906, 7222050Fax: +30210 7222889info@patrinoskilimiris.comwww.patrinoskilimiris.com

more from across site and SHARED ros bottom lb

More from across our site

A $110 million US verdict against Apple and an appellate order staying a $39 million trademark infringement finding against Amazon were also among the top talking points
Attorneys are watching how AI affects trademark registrations and whether a SCOTUS ruling from last year will have broader free speech implications
Patent lawyers explain why they will be keeping an eye on the implications of a pharma case and on changes at the USPTO in the second half of 2025
The insensitive reaction to a UK politician crying on TV proves we have a long way to go before we can say we are tackling workplace wellbeing
Adrian Percer says he was impressed by the firm’s work on billion-dollar cases as well as its culture
In our latest interview with women IP leaders, Catherine Bonner at Murgitroyd discusses technology, training, and teaching
Developments included an update in the VAR dispute between Ballinno and UEFA, the latest CMS updates, and a swathe of market moves
The LMG Life Sciences Americas Awards is thrilled to present the 2025 shortlist
A new order has brought the total security awarded to a Canadian tech company to $45 million, the highest-ever by an Indian court in an IP case
Andrew Blattman reflects on how IP practices have changed and shares his hopes for increased AI use and better performance on the stock market
Gift this article